plasmid TPqnrS-1a do not share any obvious structural similarities. A comparison between the TPqnrS-1a-associated QnrS1 protein and the 218-amino-acid proteins from Vibrio splendidus (accession no. EAP95542) and Vibrio spp. (accession no. EAQ55748)-the latter two considered as a natural reservoir of qnrS genes 5 -revealed 83% and 82% amino acid identity, respectively, and 91% amino acid similarity.
1 Organizations such as the Infectious Diseases Society of America recommend that empirical treatment of CAP should cover atypical pathogens such as L. pneumophila and Chlamydophila (Chlamydia) pneumoniae.
2 At present, macrolides and fluoroquinolones are the most active options against atypical pathogens. On the contrary, b-lactams are inactive against these pathogens.
Iclaprim is a new dihydrofolate reductase inhibitor, which recently completed enrolment in two Phase III trials of complicated skin and skin structure infections treated via intravenous administration and has recently successfully completed Phase I investigations of an oral formulation. Currently, the only clinically available antibiotic targeting dihydrofolate reductase is trimethoprim. This antibiotic can be used in combination with sulphonamides such as sulfamethoxazole, although rarely these days due to concerns over toxicity with sulfamethoxazole. At present, data on the activity of iclaprim against L. pneumophila have not been published.
Iclaprim (Arpida AG, Reinach, Switzerland), trimethoprim, sulfamethoxazole, trimethoprim/sulfamethoxazole (19:1 ratio), clarithromycin and levofloxacin (all from Sigma, Poole, UK) were investigated against 56 L. pneumophila isolates. The isolates were derived mostly from clinical material examined in hospitals or reference centres worldwide. MICs were determined using an agar dilution method. The agar consisted of 1% yeast extract (Oxoid Ltd, Basingstoke, UK), 1.3% Bacteriological Agar No. 1 (Oxoid), 5% water-lysed horse blood (Oxoid) and legionella growth supplement (Oxoid). The inoculum used was 10 4 cfu of each isolate contained in a volume of 1 mL. After 48 -72 h of incubation in air at 358C, MIC was determined as the lowest concentration of antimicrobial tested that inhibited growth of the inoculum, disregarding a single persisting colony or a faint haze caused by inoculation.
Summary MIC data are presented in Table 1 . Iclaprim was very active, with 16-fold lower MIC 50 or MIC 90 values than trimethoprim alone. Sulfamethoxazole was essentially inactive and the combination of trimethoprim and sulfamethoxazole was also less active than iclaprim, despite showing a 4-fold synergy when compared with trimethoprim alone. Iclaprim had activity similar to that observed with clarithromycin, but was less active than levofloxacin.
These data show that iclaprim has promising in vitro activity against L. pneumophila. These results, in combination with its high concentration in alveolar macrophages and epithelial lining fluid, 3 oral bioavailability and activity against other RTI pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes 4 and C. pneumoniae, 5 make iclaprim a potentially useful new agent for the treatment of RTIs.
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On 2 October 2006, a 36-year-old woman (case 1) was admitted to Auckland City Hospital with a 1-day history of dysentery, abdominal pain and fever. S. flexneri was isolated from her faeces, and the isolate was confirmed as producing an ESBL by the CLSI combination disc test. 1 Two further cases with ESBL-producing S. flexneri were subsequently identified: a 31-year-old woman, sister of case 1 (case 2), and a 5-year-old boy (case 3). Both had been assessed at a nearby hospital during the preceding 3 weeks. Public health investigation revealed that case 1 and case 2 lived in the same household (family A), whereas case 3 lived in a related household (family B). Both cases 1 and 2 lived with and cared for case 1's 4-year-old son who had developed a gastrointestinal illness on 18 September 2006. This boy did not have microbiological investigation until 3 November 2006, by which time no Shigella was isolated from his faeces. However, given his history and the relationship with the cases, he was considered to be a probable case ( probable case 4).
Twenty contacts, sharing household toilet facilities used by cases during the symptomatic phase of their illness, from three different households were identified. These contacts included 4 household contacts of case 1, case 2 and probable case 4 (family A), 11 household contacts of case 3 (family B and 
